Novonesis (Novozymes A/S): management transactions · Denmark · Finanstilsynet DK DK:novonesis-novozymes-as-1ec26e DK0060336014 DK DK · Finanstilsynet DK Mcap 172.5Bn€ Basic Materials
Browse the full management transaction log of Novonesis (Novozymes A/S), a publicly traded company based in Denmark. Shares are quoted on DK DK, under the oversight of Finanstilsynet DK. Operating in the Basic Materials sector, Novonesis (Novozymes A/S) has published 28 public disclosures. Market capitalisation: €172.5bn. The latest transaction was reported on 11 November 2021 — Purchase. Among the most active insiders: Unknown. All data is openly available.
Financial data FY ended December 2025 · cache
Analyst consensus
17 analysts 362.00 € Target 461.41 €(+25%) 560.00 €
Income statement
Revenue 4.16 Bn€
Gross profit 2.24 Bn€ 54% margin
Net income 583.6 M€ 14.2% margin
Valuation
PER (trailing) 38.7x
PER (forward) 21.2x
P/Book 2.1x
Beta 0.63
Balance sheet & cash
Market cap 172.50 Bn€
Total debt 1.80 Bn€
Free Cash Flow 750.7 M€
Debt / Equity 29%
Profitability & ownership
ROE 5.4%
ROA 3.8%
% insiders 15.8%
% institutions 31.4%
Last declaration on 11 November 2021
Declarations 28 total
Executives ● Purchase17 DK FSA
U
Unknown CSO and Executive Vice President, Research & Development Share
DK:1124431 · 10 Nov 2021
Ideal exit: 7 Aug 2022 (T+270) Executives ● Purchase28 DK FSA
U
Unknown Executive Vice President, Operations, Supply & Quality Share
DK:1122183 · 28 Oct 2021
Ideal exit: 25 Jul 2022 (T+270) Executives ● Purchase13 DK FSA
U
Unknown Spouse of board member of Novozymes Share
DK:1122075 · 28 Oct 2021
Ideal exit: 25 Jul 2022 (T+270) Executives ● Purchase28 DK FSA
Share
DK:1005046 · 17 Feb 2021
Ideal exit: 14 Nov 2021 (T+270) Executives ● Purchase28 DK FSA
Share
DK:1004383 · 12 Feb 2021
Ideal exit: 9 Nov 2021 (T+270) Executives ● Purchase13 DK FSA
Share
DK:1003359 · 3 Feb 2021
Ideal exit: 31 Oct 2021 (T+270) Executives ● Purchase13 DK FSA
Share
DK:1003185 · 3 Feb 2021
Ideal exit: 31 Oct 2021 (T+270) Executives ● Purchase17 DK FSA
U
Unknown Chairman of the Board of Directors Share
DK:960384 · 27 Oct 2020
Ideal exit: 24 Jul 2021 (T+270) Executives ● Other17 DK FSA
U
Unknown CSO and Executive Vice President, Research & Development Share
DK:959514 · 22 Oct 2020
Executives ● Purchase17 DK FSA
U
Unknown CSO and Executive Vice President, Research & Development Share
DK:954573 · 8 Sept 2020
Ideal exit: 5 Jun 2021 (T+270) Executives ● Purchase17 DK FSA
U
Unknown Vice Chairman of the Board of Directors Share
DK:954345 · 4 Sept 2020
Ideal exit: 1 Jun 2021 (T+270) Executives ● Purchase17 DK FSA
U
Unknown Vice Chairman of the Board of Directors Share
DK:954208 · 1 Sept 2020
Ideal exit: 29 May 2021 (T+270) Executives ● Purchase28 DK FSA
Share
DK:953995 · 2 Sept 2020
Ideal exit: 30 May 2021 (T+270) Executives ● Sale32 DK FSA
U
Unknown The CEO of Novo Holdings A/S serves on the Board of Directors of Novozymes A/S, and €79bn 765,000 shares @ €102,719.6145 45.55% mcap 100.0% of flow DK0060336014⌘
Share
DK:951615 · 17 Aug 2020
Executives ● Purchase28 DK FSA
U
Unknown Executive Vice President, Food & Beverage Share
DK:942216 · 26 May 2020
Ideal exit: 20 Feb 2021 (T+270) Executives ● Purchase17 DK FSA
U
Unknown COO and Executive Vice President Share
DK:941755 · 20 May 2020
Ideal exit: 14 Feb 2021 (T+270) Executives ● Sale8 DK FSA
U
Unknown The CEO of Novo Holdings A/S serves on the Board of Directors of Novozymes A/S, and Share
DK:938127 · 4 May 2020
Executives ● Purchase13 DK FSA
Share
DK:937832 · 30 Apr 2020
Ideal exit: 25 Jan 2021 (T+270) Executives ● Other8 DK FSA
Share
DK:686564 · 26 Nov 2015
Executives ● Other8 DK FSA
Share
DK:682439 · 30 Oct 2015
Executives ● Other8 DK FSA
Share
DK:645580 · 18 Feb 2015
Executives ● Other8 DK FSA
Share
DK:625185 · 22 Sept 2014
Executives ● Other8 DK FSA
Share
DK:612754 · 4 Jun 2014
Executives ● Other8 DK FSA
Share
DK:611820 · 28 May 2014
Executives ● Other8 DK FSA
Share
DK:606890 · 29 Apr 2014
25 of 28 declarations
Load more (3 remaining) About Novonesis (Novozymes A/S) Novonesis is a biotechnology company focused on developing enzymatic solutions for various sectors. It is part of Novozymes A/S, a global leader in enzymes and microorganisms.
